MedTrace Logo

CARDIOLOGIST Trial: Artificial Intelligence Enabled Electrocardiogram for Atrial Fibrillation Detection

NCT05127460 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 25732

Last updated 2023-03-28

No results posted yet for this study

Summary

This is a randomized controlled trial (RCT) to test a novel artificial intelligence (AI)-enabled electrocardiogram (ECG)-based screening tool for improving the diagnosis and management of Atrial Fibrillation.

Conditions

  • Atrial Fibrillation New Onset

Interventions

OTHER

AI-enabled ECG-based Screening Tool

Primary care clinicians in the intervention group had access to the report, which displayed whether the AI-ECG result was positive or negative. The system will send a message to corresponding physicians if positive finding.

Sponsors & Collaborators

  • National Defense Medical Center, Taiwan

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
SCREENING
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2022-10-31
Completion
2023-01-31

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127460 on ClinicalTrials.gov